Fiztasovimab (NPC-21; EV2038) 是一种全人 IgG1λ 单克隆抗体，具有抗人巨细胞病毒 (hCMV) 活性。Fiztasovimab 通过结合 hCMV包膜上糖蛋白 B 的抗原结构域 1 发挥中和活性。Fiztasovimab 还抑制 hCMV的细胞间传播。
| 生物活性 | Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 ofglycoproteinB on hCMVenvelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV[1]. |
体外研究
(In Vitro) | Fiztasovimab is isolated from Epstein-Barr virus-transformed peripheral B cells of a healthy donor[1].
Fiztasovimab has a broadly neutralizing activity against 4 laboratory strains (AD169, Towne, Davis, Merlin) and 42 Japanese clinical isolates, which included GCV-resistant isolates[1].
Fiztasovimab shows anti-hMCV activities in MRC-5 human embryonic fibroblast cells and human adult retinal pigment epithelial cells with IC50s of 13-105 ng/mL and IC90s of 0.208-1.026 μg/mL[1].
Fiztasovimab also inhibits cell-to-cell infection by hCMV isolates in adult retinal pigment epithelial cells with IC90s of 13-19 μg/mL[1].
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com